C101P: Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody
Recombinant Human IgG1 Kappa Monoclonal Antibody.
Specificity/Sensitivity: The sotrovimab biosimilar specifically binds to the spike protein of SARS-CoV-2.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by sotrovimab.C100P: Casirivimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody
Recombinant Human IgG1 Kappa Monoclonal Antibody.
Specificity/Sensitivity: The casirivimab biosimilar specifically binds to the spike protein of SARS-CoV-2.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by casirivimab.C009P: Trastuzumab Biosimilar, HER2/ErbB-2/c-neu Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody trastuzumab biosimilar specifically binds to the human HER2 / ErbB-2 / c-neu.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by trastuzumab.C001P: Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.
Specificity/Sensitivity: The monoclonal antibody bevacizumab biosimilar specifically binds to the human VEGF-A.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab.C024P: Atezolizumab Biosimilar, PD-L1 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade atezolizumab biosimilar specifically binds to the human PDL1 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by atezolizumab.C003P: Adalimumab Biosimilar, TNF alpha Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody adalimumab biosimilar specifically binds to the human TNF alpha.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by adalimumab.C022P: Eculizumab Biosimilar, Human C5 Monoclonal Antibody
Recombinant Humanized IgG2/4 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody Eculizumab biosimilar specifically binds to the human C5, the terminal complement component 5.
Applications: ELISA, functional assays such as bioanalytical PK and ADA assays.C004P: Denosumab Biosimilar, Human RANKL Monoclonal Antibody
Recombinant Humanized IgG2 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.C025P: Durvalumab Biosimilar, PD-L1 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade durvalumab biosimilar specifically binds to the human programmed cell death ligand 1 (PD-L1), blocking its interaction with PD-1 and B7-1.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by durvalumab.C030P: Daratumumab Biosimilar, CD38 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade daratumumab biosimilar specifically binds to the human CD38 protein, causing cells to apoptose via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, inhibition of mitochondrial transfer or antibody-dependent cellular phagocytosis.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by daratumumab.